Boehringer Ingelheim USA Corporation

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

Special Survey on Parkinson's Disease (PD) Patients Without Concomitant Use of L-Dopa

Completed

Conditions: Parkinson Disease

First Posted Date: 2008-02-13

Last Posted Date: 2014-06-06

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 416

Registration Number: NCT00613301

Locations: 🇯🇵
Boehringer Ingelheim Investigational Site 113, Tomiai, Japan
🇯🇵
Boehringer Ingelheim Investigational Site 35, Tokyo Ota-ku, Japan
🇯🇵
Boehringer Ingelheim Investigational Site 27, Chiba, Japan

and more 116 locations

Clinical EvaluatioN of TElmisartan-based Antihypertensive Regimen

Completed

Conditions: Hypertension
Metabolic Syndrome X

First Posted Date: 2008-02-13

Last Posted Date: 2014-05-26

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 15268

Registration Number: NCT00613314

Locations: 🇵🇭
Boehringer Ingelheim Investigational Site, Vigan City. Ilocos Sur, Philippines

Survey on PD Patients With Depressive Symptoms

Completed

Conditions: Parkinson Disease

First Posted Date: 2008-02-13

Last Posted Date: 2014-08-06

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 1089

Registration Number: NCT00614575

Locations: 🇯🇵
Boehringer Ingelheim Investigational Site 4, Yokohama, Japan
🇯🇵
Boehringer Ingelheim Investigational Site 5, Sapporo, Japan
🇯🇵
Boehringer Ingelheim Investigational Site 2, Yokohama, Japan

and more 7 locations

Safety and Efficacy of Mobic Inj. (Meloxicam) for the Patients With OA or RA: Observational Study

Completed

Conditions: Osteoarthritis
Arthritis, Rheumatoid

First Posted Date: 2008-02-12

Last Posted Date: 2013-11-01

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 425

Registration Number: NCT00612885

Locations: 🇰🇷
Boehringer Ingelheim Investigational Site, Seoul, Korea, Republic of

Efficacy and Safety of B I1356 (Linagliptin) vs. Placebo Added to Metformin Background Therapy in Patients With Type 2 Diabetes

Phase 3

Completed

Conditions: Diabetes Mellitus, Type 2

Interventions: Drug: linagliptin

First Posted Date: 2008-01-28

Last Posted Date: 2014-01-28

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 701

Registration Number: NCT00601250

Locations: 🇮🇳
1218.17.91002 Boehringer Ingelheim Investigational Site, Bangalore, India
🇮🇳
1218.17.91005 Boehringer Ingelheim Investigational Site, Bangalore, India
🇮🇳
1218.17.91012 Boehringer Ingelheim Investigational Site, Chennai, India

and more 79 locations

BI 1356 (Linagliptin) in Combination With Metformin and a Sulphonylurea in Type 2 Diabetes

Phase 3

Completed

Conditions: Diabetes Mellitus, Type 2

Interventions: Drug: placebo
Drug: linagliptin

First Posted Date: 2008-01-28

Last Posted Date: 2014-03-28

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 1058

Registration Number: NCT00602472

Locations: 🇧🇪
1218.18.32006 Boehringer Ingelheim Investigational Site, Edegem, Belgium
🇧🇪
1218.18.32002 Boehringer Ingelheim Investigational Site, Huy, Belgium
🇨🇦
1218.18.01003 Boehringer Ingelheim Investigational Site, Vancouver, British Columbia, Canada

and more 97 locations

Long-term Safety Study of Open-label Pramipexole Extended Release (ER) in Patients With Early Parkinson´s Disease (PD).

Phase 3

Completed

Conditions: Parkinson Disease

Interventions: Drug: Placebo
Drug: Pramipexole

First Posted Date: 2008-01-28

Last Posted Date: 2014-06-09

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 511

Registration Number: NCT00601523

Locations: 🇺🇸
248.633.01016 Boehringer Ingelheim Investigational Site, La Jolla, California, United States
🇺🇸
248.633.01013 Boehringer Ingelheim Investigational Site, Oxnard, California, United States
🇦🇹
248.633.43004 Boehringer Ingelheim Investigational Site, Wien, Austria

and more 116 locations

Long-term Safety Study of Open-label Pramipexole ER in Patients With Advanced PD

Phase 3

Completed

Conditions: Parkinson Disease

Interventions: Drug: Placebo
Drug: Pramipexole

First Posted Date: 2007-12-20

Last Posted Date: 2014-05-16

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 391

Registration Number: NCT00577460

Locations: 🇮🇳
248.634.91001 Boehringer Ingelheim Investigational Site, Delhi, India
🇭🇺
248.634.36005 Boehringer Ingelheim Investigational Site, Györ, Hungary
🇭🇺
248.634.36003 Boehringer Ingelheim Investigational Site, Kecskemét, Hungary

and more 67 locations

Sodium Picosulphate vs. Placebo in Functional Constipation

Phase 3

Completed

Conditions: Constipation

First Posted Date: 2007-12-19

Last Posted Date: 2014-05-16

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 367

Registration Number: NCT00576810

Locations: 🇩🇪
1062.7.4927 Boehringer Ingelheim Investigational Site, Dortmund, Germany
🇩🇪
1062.7.4949 Boehringer Ingelheim Investigational Site, Dresden, Germany
🇩🇪
1062.7.4953 Boehringer Ingelheim Investigational Site, Hamburg, Germany

and more 40 locations

Tiotropium Once Daily 18 Mcg Versus Salmeterol Twice Daily 50 Mcg on Time to First Exacerbation in COPD Patients.

Phase 4

Completed

Conditions: Pulmonary Disease, Chronic Obstructive

Interventions: Drug: Tiotropium bromide
Drug: Salmeterol
Drug: Placebo Salmeterol
Drug: Placebo Tiotropium

First Posted Date: 2007-11-26

Last Posted Date: 2013-12-24

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 7376

Registration Number: NCT00563381

Locations: 🇦🇹
205.389.1020 Boehringer Ingelheim Investigational Site, Feldbach, Austria
🇦🇹
205.389.1002 Boehringer Ingelheim Investigational Site, Wien, Austria
🇨🇿
205.389.1204 Boehringer Ingelheim Investigational Site, Brno-Kralovo Pole, Czech Republic

and more 749 locations

© Copyright 2024. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy